MTD, Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors

Inclusion Criteria: * 19+ years old * Diagnosed with advanced solid tumor histologically/cytologically * Patient without standard therapies or who have failed approved standard therapies * Those with a disease that is measurable and/or evaluable with the appropriate imaging examination according to RECIST v1.1 * ECOG performance status 0 to 2 * Patients with the suitable marrow, kidney, liver functions, blood coagulation and glycemic control functions * Patients whose Life expectancy is over 12 weeks * Patients who signed the agreement to voluntarily participate in this study Exclusion Criteria: * Patients who have received a major surgery, radiotherapy, chemotherapy, biologic therapy, targeted therapy, cancer immunotherapy or metabolic therapy within specified weeks counting from the initial administration of the IPs * Diagnosed with a malignant tumor other than the relevant disease in the last 5 years from the initial administration of the IPs * Toxicity level has not been recovered to CTCAE Grade 1 or lower * Has uncontrolled metastasis to the CNS * Suspected of having a serious infectious disease, paralysis of intestine, bowel obstruction, interstitial pneumonia or pulmonary fibrosis * Had serious GI bleed or a disease that may affect the absorption of the oral drug in the past 4 weeks * Considered as having a serious heart disease by the investigator or a serious internal disease * Has administered a drug from another study within 4 weeks * Has administered live vaccines within 4 weeks * Has abused substance or alcohol within 12 weeks * Has a serious trauma * Has a history or currently has a type 1 or 2 diabetes * Has a history of lactic acidosis * Has glucose-6-phosphate dehydrogenase deficiency * Has HIV or active or an active hepatitis B or C * Has a history of psychological condition that could threaten observation of this protocol * Has a history of hypersensitive reaction to the main ingredient or component of the IP or biguanide class drugs * Being pregnant or a lactating woman, or (+) pregnancy test * A female subject of a childbearing age who plans to get pregnant or disagrees to use recommended contraceptions * Has not agreed to abstain from alcohol * Considered as unsuitable for the study for other reason by the investigator